Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析

◆英語タイトル:Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH259175FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥48,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Karyopharm Therapeutics Inc (KPTI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Karyopharm Therapeutics Inc (Karyopharm Therapeutic) discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitors of nuclear export compounds that combat the nuclear export of XPO1 protein. Karyopharm’s lead product include Xpovio developed for treatment of multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma. Its pipeline drug candidates include selinexor, verdinexor, eltanexor, and KPT-9274. Karyopharm drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and endometrial cancer. The company has operations in the US, Israel and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc Key Recent Developments

Feb 04,2021: Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 2021
Jan 11,2021: Karyopharm announces preliminary unaudited fourth quarter and full year 2020 total revenues and provides commercial update
Dec 15,2020: Karyopharm appoints Michael Mano as Senior Vice President, General Counsel and reports inducement grants under Nasdaq listing rule 5635(c)(4)
Nov 02,2020: Karyopharm reports third quarter 2020 financial results and highlights recent company progress
Aug 31,2020: Karyopharm Therapeutics appoints Christy J. Oliger to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Karyopharm Therapeutics Inc – Key Facts
Karyopharm Therapeutics Inc – Key Employees
Karyopharm Therapeutics Inc – Key Employee Biographies
Karyopharm Therapeutics Inc – Major Products and Services
Karyopharm Therapeutics Inc – History
Karyopharm Therapeutics Inc – Company Statement
Karyopharm Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Karyopharm Therapeutics Inc – Business Description
Product Category: License and Other Revenue
Performance
Product Category: Product Revenue
Performance
R&D Overview
Karyopharm Therapeutics Inc – Corporate Strategy
Karyopharm Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Karyopharm Therapeutics Inc – Strengths
Karyopharm Therapeutics Inc – Weaknesses
Karyopharm Therapeutics Inc – Opportunities
Karyopharm Therapeutics Inc – Threats
Karyopharm Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 04, 2021: Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 2021
Jan 11, 2021: Karyopharm announces preliminary unaudited fourth quarter and full year 2020 total revenues and provides commercial update
Dec 15, 2020: Karyopharm appoints Michael Mano as Senior Vice President, General Counsel and reports inducement grants under Nasdaq listing rule 5635(c)(4)
Nov 02, 2020: Karyopharm reports third quarter 2020 financial results and highlights recent company progress
Aug 31, 2020: Karyopharm Therapeutics appoints Christy J. Oliger to its Board of Directors
Aug 04, 2020: Karyopharm reports second quarter 2020 financial results and highlights recent company progress
May 05, 2020: Karyopharm reports first quarter 2020 financial results and highlights recent company progress
Mar 12, 2020: Karyopharm expands executive leadership team with the appointment of John Demaree as Chief Commercial Officer
Feb 13, 2020: Karyopharm reports fourth quarter and full year 2019 financial results and highlights recent company progress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Karyopharm Therapeutics Inc, Key Facts
Karyopharm Therapeutics Inc, Key Employees
Karyopharm Therapeutics Inc, Key Employee Biographies
Karyopharm Therapeutics Inc, Major Products and Services
Karyopharm Therapeutics Inc, History
Karyopharm Therapeutics Inc, Subsidiaries
Karyopharm Therapeutics Inc, Key Competitors
Karyopharm Therapeutics Inc, Ratios based on current share price
Karyopharm Therapeutics Inc, Annual Ratios
Karyopharm Therapeutics Inc, Annual Ratios (Cont...1)
Karyopharm Therapeutics Inc, Interim Ratios
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • General Dynamics Corporation:戦略・SWOT・企業財務分析
    General Dynamics Corporation - Strategy, SWOT and Corporate Finance Report Summary General Dynamics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • University of California:製薬・医療:M&Aディール及び事業提携情報
    Summary University of California is a public research university system that offers educational and research services. The university’ services include research and teaching services, graduate, undergraduate and postgraduate courses, doctoral programs and courses, master’s programs, degree programs, …
  • Inter RAO UES (IRAO):電力:M&Aディール及び事業提携情報
    Summary Inter RAO UES (Inter RAO) is a vertically integrated energy utility. It has presence in the energy value chain, including electricity generation, transmission, sales, trading and engineering. The company generates power in thermal, hydro, and co-generation plants; and supplies that energy on …
  • Bharat Heavy Electricals Ltd (BHEL):企業の財務・戦略的SWOT分析
    Bharat Heavy Electricals Ltd (BHEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • M.M.Warburg & Co Kgaa:企業の戦略・SWOT・財務分析
    M.M.Warburg & Co Kgaa - Strategy, SWOT and Corporate Finance Report Summary M.M.Warburg & Co Kgaa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Infineon Technologies AG:企業の戦略・SWOT・財務情報
    Infineon Technologies AG - Strategy, SWOT and Corporate Finance Report Summary Infineon Technologies AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • J Uriach Y Compania SA-製薬・医療分野:企業M&A・提携分析
    Summary J Uriach Y Compania SA (Uriach) is a pharmaceutical company that offers food supplements, cosmetics and OTC products. It also researches, develops and manufactures active ingredients for the pharmaceutical market. Uriach provides antiflatulents, antifungals, mineral supplements and antiplate …
  • Tenaska Inc:発電所・企業SWOT分析
    Tenaska Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Bank of Montreal:戦略・SWOT・企業財務分析
    Bank of Montreal - Strategy, SWOT and Corporate Finance Report Summary Bank of Montreal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PPL Corp (PPL):企業の財務・戦略的SWOT分析
    PPL Corp (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Cytogel Pharma LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Cytogel Pharma LLC (Cytogel Pharma) is a biopharmaceutical development company that provides platform technologies and product candidates. The company offers novel analgesic product candidates and polymer and hydrogel drug delivery platform technologies. Its analgesic product candidates offe …
  • VAALCO Energy Inc (EGY):石油・ガス:M&Aディール及び事業提携情報
    Summary VAALCO Energy, Inc. (VAALCO) is an upstream oil and gas company. It acquires, explores, develops and produces crude oil and natural gas from assets. The company conducts the exploration activities as operator in Gabon and as a non-operator in Equatorial Guinea, West Africa. The company’s ass …
  • Gran Tierra Energy Inc (GTE):石油・ガス:M&Aディール及び事業提携情報
    Summary Gran Tierra Energy Inc (Gran Tierra) is an independent energy company. It acquires, explores, and develops oil and gas fields. The company produces crude oil, natural gas, and oil equivalent resources from its fields. Gran Tierra has onshore oil and gas properties in Colombia. It sells oil t …
  • Racetrac Petroleum, Inc.:企業の戦略・SWOT・財務分析
    Racetrac Petroleum, Inc. - Strategy, SWOT and Corporate Finance Report Summary Racetrac Petroleum, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sungrow Power Supply Co Ltd (300274):企業の財務・戦略的SWOT分析
    Summary Sungrow Power Supply Co Ltd (Sungrow) is a renewable energy company that manufactures power supply equipment for solar PV (photovoltaic) and wind power projects. The company's products include PV inverters, floating systems, storage systems and accessories. It offers services such as constru …
  • Sanquin Blood Supply Foundation:医療機器:M&Aディール及び事業提携情報
    Summary Sanquin Blood Supply Foundation (Sanquin) is a provider of blood bank and diagnostic services, plasma derived products, tissues and cells and reagents. It offers blood-related lab tests for hospitals, blood banks, obstetricians practices, pharmaceutical companies, insurance organizations, an …
  • Histocell SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Histocell SL (Histocell), a subsidiary of Noray Biosciences Group, is a biopharmaceutical company that develops cell therapy and tissue engineering products for regenerative medicine. The company provides Wharton Gel Complex, medical devices, contract manufacturing and cell therapy programs, …
  • Shanghai Pharmaceutical Co Ltd (601607):医療機器:M&Aディール及び事業提携情報
    Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. The company carries out the research and development, manufacture and sale of pharmaceutical products for treating HER2 positive advanced breast cancer, systemic a …
  • Housing Development Finance Corporation Limited:戦略・SWOT・企業財務分析
    Housing Development Finance Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Housing Development Finance Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Tethys Oil AB (TETY):企業の財務・戦略的SWOT分析
    Summary Tethys Oil AB (Tethys Oil) is an upstream oil and gas company that offers exploration, development and production of oil and natural gas reserves. The company holds onshore exploration licences in Lithuania and France. Tethys Oil holds Gargzdai license, Rietavas license and Raseiniai license …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆